Advertisement
Advertisement
LGND
Ligand Pharmaceuticals Inc.
224.86
USDSponsored
-7.46
-3.21%
Apr 29, 15:59 UTC -4
Closed
After-Market
224.54
-0.32
-0.14%
LGND Earnings Reports
Positive Surprise Ratio
LGND beat 37 of 40 last estimates.
93%
Next Report
Date of Next Report
May 07, 2026
Estimate for Q1 26 (Revenue/ EPS)
$60.15M
/$2.09
Implied change from Q4 25 (Revenue/ EPS)
+0.82%
/+3.47%
Implied change from Q1 25 (Revenue/ EPS)
+32.69%
/+57.14%
Ligand Pharmaceuticals Inc. earnings per share and revenue
On Feb 26, 2026, LGND reported earnings of 2.02 USD per share (EPS) for Q4 25, beating the estimate of 1.59 USD, resulting in a 26.84% surprise. Revenue reached 59.67 million, compared to an expected 56.70 million, with a 5.23% difference. The market reacted with a +2.50% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 2.09 USD, with revenue projected to reach 60.15 million USD, implying an increase of 3.47% EPS, and increase of 0.82% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Viking Therapeutics, Inc
Report Date
Apr 29, 2026 For Q1 26
Estimate
-$1.03
Actual
-$1.37
Surprise
-32.46%
Regeneron Pharmaceuticals Inc
Report Date
Apr 29, 2026 For Q1 26
Estimate
$9.06
Actual
$9.47
Surprise
+4.45%
Biogen Inc. Common Stock
Report Date
Apr 29, 2026 For Q1 26
Estimate
$3.07
Actual
$3.57
Surprise
+16.28%
Incyte Genomics Inc
Report Date
Apr 28, 2026 For Q1 26
Estimate
$1.39
Actual
$1.81
Surprise
+29.43%
Agios Pharmaceuticals, Inc.
Report Date
Apr 29, 2026 For Q1 26
Estimate
-$1.83
Actual
-$1.69
Surprise
+7.99%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Apr 28, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.13
Surprise
+60.74%
NeoGenomics, Inc.
Report Date
Apr 28, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+38.89%
MiMedx Group, Inc
Report Date
Apr 29, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.05
Surprise
-77.94%
Nautilus Biotechnolgy, Inc. Common Stock
Report Date
Apr 28, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.12
Surprise
+18.86%
Amarin Corp Plc
Report Date
Apr 29, 2026 For Q1 26
Estimate
$0.08
Actual
-$0.09
Surprise
-203.81%
FAQ
What were Ligand Pharmaceuticals Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Ligand Pharmaceuticals Inc. reported EPS of $2.02, beating estimates by 26.84%, and revenue of $59.67M, 5.23% above expectations.
How did the market react to Ligand Pharmaceuticals Inc.'s Q4 2025 earnings?
The stock price moved up 2.5%, changed from $191.39 before the earnings release to $196.17 the day after.
When is Ligand Pharmaceuticals Inc. expected to report next?
The next earning report is scheduled for May 07, 2026.
What are the forecasts for Ligand Pharmaceuticals Inc.'s next earnings report?
Based on 5
analysts, Ligand Pharmaceuticals Inc. is expected to report EPS of $2.09 and revenue of $60.15M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement